Novo Nordisk to pull Tresiba from German market on price disagreement

1 July 2015

Danish diabetes care giant Novo Nordisk (NOV: N) says it will cease distribution of its once-daily basal insulin Tresiba (insulin degludec) in Germany.

The decision follows a negative outcome of price negotiations with the GKV-Spitzenverband, the German national association of statutory health insurance funds. In order to ensure a safe switch to another insulin treatment for the 40,000 people with diabetes currently using Tresiba, Novo Nordisk will continue supplying the product until the end of September 2015.

Insurer set price at that of ordinary human insulin

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK